Drug Search Results
More Filters [+]

Ertugliflozin

Alternative Names: ertugliflozin, STEGLATRO, segluromet, steglujan
Latest Update: 2024-11-22
Latest Update Note: Clinical Trial Update

Product Description

Ertugliflozin is used along with diet and exercise, and sometimes with other medications, to lower blood sugar levels in people with type 2 diabetes (condition in which blood sugar is too high because the body does not produce or use insulin normally). Ertugliflozin is in a class of medications called sodium-glucose co-transporter 2 (SGLT2) inhibitors. It lowers blood sugar by causing the kidneys to get rid of more glucose in the urine. Ertugliflozin is not used to treat type 1 diabetes (condition in which the body does not produce insulin and, therefore, cannot control the amount of sugar in the blood) or diabetic ketoacidosis (a serious condition that may develop if high blood sugar is not treated). (Sourced from: https://medlineplus.gov/druginfo/meds/a618011.html)

Mechanisms of Action: SGLT2 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Canada | Chile | Croatia | Cyprus | Czech | Denmark | Egypt | Estonia | European Medicines Agency | Finland | Germany | Greece | Hong Kong | Hungary | Iceland | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Netherlands | Norway | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | United Arab Emirates | United Kingdom | United States

Approved Indications: Acidosis | Diabetic Ketoacidosis | General Diabetes | Type 2 Diabetes | Pancreatitis | Acidosis | Diabetic Ketoacidosis | General Diabetes | Type 2 Diabetes

Known Adverse Events: Headache | Asthenia | Diarrhea | Flatulence | Nasopharyngitis | Pharyngitis | Respiratory Tract Infections | Hypoglycemia

Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Ertugliflozin

Countries in Clinic: Belgium, Canada, Colombia, Costa Rica, Dominican Republic, France, Guatemala, Hungary, Israel, Italy, Korea, Malaysia, Mauritius, Mexico, Philippines, Poland, Russia, Saudi Arabia, Turkey, Ukraine, United Arab Emirates, United Kingdom, United States

Active Clinical Trial Count: 8

Highest Development Phases

Phase 3: Heart Failure|Mitral Valve Insufficiency|Type 2 Diabetes|Ventricular Dysfunction, Left

Phase 1: Atherosclerosis|Insulin Resistance

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Ertugliflozin versus Placebo in Paediatric Type 2 Diabetes

P3

Unknown status

Type 2 Diabetes

2025-11-26

MK-8835-059

P3

Unknown Status

Type 2 Diabetes

2025-09-06

MK-8835-059

P3

Active, not recruiting

Type 2 Diabetes

2025-04-23

MISP59625

P2

Recruiting

Heart Failure

2025-01-31

Recent News Events